5 recruiting, 3 completed, 1 active not recruiting. 9 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Recruiting 5, Completed 3, Active not recruiting 1 |
| Phase 1 | 2 | Active not recruiting 1, Recruiting 1 |
Follow Syntrix Biosystems, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer Atezolizumab, CXCR1/2 Inhibitor SX-682, Biospecimen Collection - Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma | Phase 2 | Recruiting | University of Washington | 32 | 2026-10-06 | 2026-10-13 |
| Investigating SX-682 in Combination With Apalutamide in Metastatic Castration-resistant Prostate Cancer SX-682, Apalutamide - Metastatic Castrate-Resistant Prostate Cancer (mCRPC) | Phase 1 / Phase 2 | Recruiting | Institute of Cancer Research, United Kingdom | 78 | 2025-04-28 | 2026-09-08 |
| Study of SX-682 Plus Enzalutamide in Men With ARPI-Resistant Metastatic Castration Resistant Prostate Cancer SX-682, Enzalutamide - Metastatic Castration-resistant Prostate Cancer | Phase 2 | Recruiting | Syntrix Biosystems, Inc. | 53 | 2024-11-18 | 2026-06-02 |
| A Neoadjuvant Study of Tislelizumab and SX-682 for Resectable Pancreas Cancer Tislelizumab, SX-682 - Pancreatic Cancer | Phase 2 | Recruiting | Lei Zheng | 25 | 2023-11-08 | 2026-10-07 |
| SX-682 With Pembrolizumab for the Treatment of Metastatic or Recurrent Stage IIIC or IV Non-Small Cell Lung Cancer Biopsy, Biospecimen Collection, Computed Tomography - Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma | Phase 2 | Recruiting | University of Washington | 30 | 2023-04-06 | 2026-06-17 |
| SX-682 and Nivolumab for the Treatment of RAS-Mutated, MSS Unresectable or Metastatic Colorectal Cancer, the STOPTRAFFIC-1 Trial CXCR1/2 Inhibitor SX-682, Nivolumab - Metastatic Colon Adenocarcinoma, Metastatic Colorectal Carcinoma | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 51 | 2020-10-14 | 2026-07-20 |
| Omnitram Safety and Efficacy in the Treatment of Diabetic Neuropathy Omnitram Oral Tablet, Placebo Oral Tablet - Diabetic Neuropathies, Neuropathic Pain | Phase 2 | Completed | Syntrix Biosystems, Inc. | 55 | 2018-11-15 | 2021-09-30 |
| Once-Weekly Oral Aminopterin for the Treatment of Subjects With Moderate-To-Severe Psoriasis LD-Aminopterin oral capsule, Placebo oral capsule - Psoriasis | Phase 2 | Completed | Syntrix Biosystems, Inc. | 19 | 2018-11-01 | 2023-04-14 |
| Aminopterin Dose Finding Treatment for Methotrexate-Naïve Rheumatoid Arthritis LD-aminopterin, placebo - Rheumatoid Arthritis | Phase 2 | Completed | Syntrix Biosystems, Inc. | 175 | 2013-02-01 | 2015-05-20 |
Carcinoma, Non-Small-Cell Lung (2) · Lung Neoplasms (2) · Adenocarcinoma (1) · Agnosia (1) · Arthritis, Rheumatoid (1) · Autoimmune Diseases (1) · Chronic Pain (1) · Colonic Neoplasms (1) · Colorectal Neoplasms (1) · Diabetic Neuropathies (1) · Neuralgia (1) · Pancreatic Neoplasms (1) · Prostatic Neoplasms (1) · Psoriasis (1) · Rectal Neoplasms (1)
Biopsy (2) · Magnetic Resonance Spectroscopy (2) · Specimen Handling (2) · Nivolumab (1) · apalutamide (1) · atezolizumab (1) · enzalutamide (1) · pembrolizumab (1) · tislelizumab (1)
United States (7) · Switzerland (1) · Ukraine (1) · United Kingdom (1)
Stuart Kahn, MD (2) · Alisha Bent, MD (1) · Christina Baik, MD, MPH (1) · Christina S. Baik (1) · Lei Zheng, MD (1) · Professor Johann de Bono, MB ChB, FRCP, MSc, PhD, FMedSc (1) · Stuart Kahn, MD, MS (1) · Syntrix Biosystems (1)
P50CA228944 (2), R44CA278187 (1), R44DA040378 (1), U44AI114473 (1)